Companies Dominating the SGLT2 Inhibitors Treatment Landscape
- Novartis International AG
- Company overview
- Business strategy
- Key product offerings
- Financial performances
- Key performance indicators
- Risk analysis
- Recent development
- Regional presence
- SWOT analysis
- Boehringer Ingelheim GmbH
- Janssen pharmaceuticals
- GRUPO TECNIMEDE
- Unichem Laboratories Ltd.
- Edificio Bluepharma
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of SGLT2 inhibitors treatment is evaluated at USD 7.44 billion.
The SGLT2 inhibitors treatment market size was valued at USD 6.42 billion in 2024 and is set to exceed USD 21.14 billion by 2037, registering over 9.6% CAGR during the forecast period i.e., between 2025-2037. Growing Concern for the Prevalence of diabetes mellitus will drive the market growth.
North America industry is predicted to account for largest revenue share of 32% by 2037, impelled by increasing prevalence of obesity and lifestyle changes in the region.
The major players in the market are Novartis International AG, Financial performancesBoehringer Ingelheim GmbH, Janssen pharmaceuticals, GRUPO TECNIMEDE, Unichem Laboratories Ltd., Edificio Bluepharma
